Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing of the first patient in a Phase Ib/II clinical study for its injectable STSA-1002, an anti-human complement protein C5a (hC5a) monoclonal antibody (mAb). The drug candidate is under evaluation as a potential treatment for acute respiratory distress syndrome (ARDS).
ARDS is characterized by diffuse pulmonary interstitial and alveolar edema triggered by a variety of intrapulmonary and extrapulmonary pathogenic factors excluding those of cardiogenic origin. The pathogenesis of ARDS is multifaceted, involving immune cell activation, coagulation, regulation of vascular endothelial permeability, endothelial and epithelial cell barrier functions, and ion channel function regulation. As a multi-effect mediator, C5a plays a significant role in the disease process, and STSA-1002, by inhibiting C5a, can effectively block its chemotactic activity towards neutrophils, the formation of neutrophil extracellular traps (NETs), and fibrin production.- Flcube.com
